EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

CLUSTER OF DIFFERENTIATION 3 ZETA-CHAIN EXPRESSION AS A POTENTIAL BIOMARKER OF IMMUNE DYSFUNCTION IN AN INDIAN BREAST CANCER COHORT: CORRELATION WITH INTERLEUKIN-6 AND INTERLEUKIN-13 LEVELS

ADITI SHARMA, KARANPREET BHUTANI, REENA V SAINI, MAYURESH HANMANTRAO BARURE

Asian Journal of Pharmaceutical and Clinical Research · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Objectives: This study aimed to evaluate cluster of differentiation 3 zeta (CD3ζ) expression in peripheral blood mononuclear cells (PBMC) and serum interleukin-6 (IL)-6 and IL-13 levels and to determine their association in breast cancer (BC) patients. Methods: To determine the expression of CD3ζ in 45 patients with BC patients diagnosed at any stage, without undergoing treatment, and 15 age-matched controls were included in the study. PBMCs were isolated, and flow cytometry analysis was done. Serum samples were collected from the same patients and healthy controls to check for IL-6 and IL-13 through enzyme-linked immunosorbent assay. Results: A total of 60 participants (45 BC patients and 15 healthy controls) were included. BC patients showed significantly reduced CD3ζ mean fluorescence intensity (MFI) and CD3ζ⁺ T-cell percentages compared with controls (p≤0.001), while serum IL-6 and IL-13 levels were significantly elevated (both p

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
ADITI SHARMA, KARANPREET BHUTANI, REENA V SAINI, MAYURESH HANMANTRAO BARURE
Quelle
Asian Journal of Pharmaceutical and Clinical Research
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2455-3891, 0974-2441
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

ADITI SHARMA, KARANPREET BHUTANI, REENA V SAINI, MAYURESH HANMANTRAO BARURE (2026). CLUSTER OF DIFFERENTIATION 3 ZETA-CHAIN EXPRESSION AS A POTENTIAL BIOMARKER OF IMMUNE DYSFUNCTION IN AN INDIAN BREAST CANCER COHORT: CORRELATION WITH INTERLEUKIN-6 AND INTERLEUKIN-13 LEVELS. Asian Journal of Pharmaceutical and Clinical Research. https://doi.org/10.22159/ajpcr.2026v19i9.60363
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1